Regulatory FDA Tracker

First FDA Inspection Readiness for CDMOs

FDA Tracker ingests every FDA enforcement action and filters them by facility type, dosage form, and therapeutic area. AI agents parse, summarise, and score each action so your quality team prepares with the same structured intelligence that multi-site manufacturers use.

Key Highlights

01 483 patterns filtered by CDMO, biologics, and cell therapy facility type
02 Peer CDMO enforcement profiles — what FDA cites at facilities like yours
03 Custom FDA inspection checklists for viral vector, aseptic, and cell therapy
04 Investigator and district intelligence for your FDA region

Regulatory Context

What Form 483 Data Would Have Shown

21 CFR 211.22 Quality System Gaps
1 / 6

Quality system missing written procedures for stability testing, change control, and environmental monitoring

Quality control unit lacked written procedures across stability sample testing, change control, and environmental monitoring. Stability samples were stored in locations accessible to all QC and R&D personnel with no controls to prevent selection errors.

Aurolige Pharma LLC · 2025-04-10
21 CFR 211.22 Quality Oversight
2 / 6

Inadequate quality oversight for specification investigations, training, and record-keeping

Quality oversight was inadequate across three areas: specification investigations lacked complete documentation, training records did not demonstrate competency, and record-keeping practices did not meet SOP requirements.

Humacyte Global, Inc. · 2024-04-05
21 CFR 211.113 Aseptic Controls
3 / 6

Sterile contamination prevention procedures not established or followed

Procedures designed to prevent microbiological contamination of sterile drug products were not established and followed. The facility's contamination control strategy had gaps in aseptic processing controls that could compromise product sterility.

GSK Vaccines GmbH · 2024-03-06
21 CFR 211.192 Batch Review Gaps
4 / 6

Unexplained batch record discrepancies not thoroughly reviewed in biologics manufacturing

The facility failed to thoroughly review unexplained discrepancies in batch records, whether or not the batch had already been distributed.

ADMA Biologics, Inc · 2024-12-11
21 CFR 211.198 Complaint Investigation
5 / 6

Lack-of-efficacy complaints not fully investigated — no retention sample testing performed

The facility received approximately 20 lack-of-efficacy complaints over two years. Investigation identified no production deficiencies, yet the firm did not test any retention samples to determine whether reported adverse events were related to product quality.

Empower Pharmacy · 2024-08-28
21 CFR 211.84 Supplier Qualification
6 / 6

No identity testing on incoming components and no supplier validation since facility inception

The firm had not performed identity tests on incoming components, lacked confirmatory testing procedures, and had no process for testing active pharmaceutical ingredients upon receipt. Incoming materials were accepted based solely on supplier certificates of analysis.

GenoGenix, LLC · 2025-07-18

The Problem

The First-Inspection Gap

Challenge 1 1 / 6

No Institutional Inspection Memory

  • Facilities with 10+ years of FDA history have institutional memory no SOP can replicate
  • First-time inspected facilities receive 483s at significantly higher rates
  • Passing a Health Canada or EMA audit does not equal FDA readiness
Challenge 2 2 / 6

One Person Is the Entire Regulatory Intelligence Operation

  • FDA publishes 4,000+ 483 observations per year — one person covers a fraction
  • When that person is pulled into audits or production issues, intelligence stops
  • Manual categorisation via email creates no auditable record of action
Challenge 3 3 / 6

Health Canada or EMA Audit ≠ FDA Inspection Readiness

  • FDA's QSIT framework structures inspections differently from Health Canada's approach
  • 21 CFR Part 11 data integrity expectations are more prescriptive than EU GMP equivalents
  • FDA investigators have individual citation patterns — a dimension absent in other jurisdictions
Challenge 4 4 / 6

No Benchmark for What FDA Cites at Similar Facilities

  • Citation patterns differ dramatically by facility type and dosage form
  • Emerging categories like cell and gene therapy have evolving, uncodified expectations
  • Without benchmarking data, teams cannot prioritise pre-inspection focus areas
Challenge 5 5 / 6

Clinical-to-Commercial Transition Introduces New FDA Scrutiny

  • PAIs focus on consistent commercial-scale manufacturing, not just clinical batch capability
  • Process validation requirements escalate to full lifecycle validation with ongoing verification
  • Quality systems adequate for clinical scale often gap in CAPA, trending, and APR at commercial scale
Challenge 6 6 / 6

Generic Audit Prep Checklists Miss Facility-Specific Risk

  • A 300-question generic checklist treats cleaning validation and complaints equally regardless of citation frequency
  • Checklists do not adapt to your dosage form or manufacturing technology
  • Pre-inspection weeks are spent on low-risk areas while high-risk gaps remain unaddressed

First FDA Inspection Preparation in FDA Tracker

1

Industry-Wide Enforcement Intelligence Filtered for Your Facility Type

FDA Tracker ingests every 483, warning letter, import alert, and recall as published. The platform filters by facility type, dosage form, and therapeutic area so your quality team sees only what FDA is citing at facilities like yours.

CDMO/Biologics Classification Dosage Form Matching Therapeutic Area Tagging Relevance Scoring

FDA Sources

483 Observations
Warning Letters
Import Alerts
Recalls

Processing

Facility Type Filter
Dosage Form Match
Relevance Scoring

Filtered Output

CDMO Intelligence Feed
Risk Profile
2

Peer CDMO & Biologics Benchmarking

FDA Tracker builds enforcement profiles for every CDMO, biologics manufacturer, and cell therapy facility in the FDA database. When a peer CDMO receives a 483, your team sees the observation and whether the same gap could exist at your facility.

CDMO Peer Identification Citation Pattern Comparison Gap Similarity Scoring Risk Signal Detection
3

Six System Audit Readiness Mapping

Every observation is tagged to FDA's Six System inspection framework. System owners each see only observations relevant to their area, weighted by current citation frequency.

QSIT System Tagging Citation Frequency Weighting System Owner Routing Trend Detection
4

Custom Keyword Checklists for Your Processes

Enter keywords specific to your manufacturing processes — "viral vector", "cell therapy", "aseptic filling" — and FDA Tracker generates a curated list of relevant observations with an exportable PDF checklist.

Keyword Matching Observation Curation PDF Generation Relevance Ranking
5

Investigator & District Intelligence

FDA Tracker profiles every FDA investigator — citation patterns, focus areas, and facility types inspected. Know which investigators are active in your district and what they cited at their last five inspections.

Citation Pattern Analysis District Profiling Focus Area Identification Pre-Inspection Briefing
6

Continuous Monitoring as You Scale

As your CDMO transitions from clinical to commercial manufacturing, FDA Tracker continuously surfaces new enforcement signals relevant to your evolving operations. When FDA begins citing a new pattern at commercial-scale facilities, your team knows within hours.

Real-Time Monitoring Profile Evolution Tracking Emerging Signal Detection Scale-Transition Alerts

The Solution

How FDA Tracker Solves This

Structured enforcement intelligence that replaces generic preparation with facility-type-specific, enforcement-data-weighted inspection readiness.

FDA Tracker Intelligence Platform

Every FDA Enforcement Action — Filtered for CDMO & Biologics Facilities

FDA Tracker ingests 483 observations, warning letters, import alerts, recalls, and guidances in real-time, filtered by facility type, dosage form, and therapeutic area.

  • 148,000+ historical enforcement records filtered by CDMO, biologics, and cell therapy facility type
  • AI-generated summaries with entity extraction and regulatory classification
  • Peer CDMO enforcement profiles showing citation patterns at similar facilities
Custom Audit Readiness Checklists

Process-Specific Checklists Weighted by Current Enforcement Trends

Generate audit readiness checklists from keywords specific to your processes — viral vector, aseptic filling, cell therapy — weighted by citation frequency and exportable as PDF.

  • Custom keyword filtering across the full observation database
  • Citation frequency weighting — high-risk areas surface first
  • Six System tagging so each system owner gets a focused checklist
Investigator & District Intelligence

Know What Inspectors Focus On Before Your First Inspection

Profiles for every FDA investigator — inspection history, citation patterns, focus areas, and facility types inspected — giving CDMOs without inspection history the closest substitute for institutional memory.

  • Investigator profiles with citation patterns and focus area analysis
  • FDA district intelligence showing which facilities were recently inspected in your area
  • Pre-inspection briefing documents generated from investigator history
Continuous Regulatory Monitoring

Evolving Intelligence as You Scale from Clinical to Commercial

As your CDMO scales to commercial manufacturing, FDA Tracker continuously surfaces emerging enforcement patterns — process validation citations, batch review expectations, and PAI preparation signals.

  • Real-time alerts when FDA begins citing new patterns at commercial-scale facilities
  • Enforcement trend tracking specific to your evolving manufacturing profile
  • Multi-channel delivery — email digests, in-app notifications, team routing

Before & After

The Shift

Dimension
Without FDA Tracker
With FDA Tracker
Industry intelligence
One person reading warning letters manually, forwarding via email — covering a fraction of FDA output
Every FDA enforcement action ingested, scored for relevance, and filtered for your facility type automatically
Peer benchmarking
No visibility into what FDA is citing at other CDMOs, biologics, or cell therapy facilities
Continuous peer CDMO enforcement profiles with gap similarity scoring
Audit checklists
Generic 300-question GMP checklists that treat every CFR section equally
Custom keyword checklists weighted by current enforcement frequency in your dosage form category
Investigator knowledge
Unknown until FDA Form 482 is presented — no institutional memory to draw from
Investigator profiles with citation patterns, focus areas, and district assignment history
Regulatory gap between jurisdictions
Assumption that passing Health Canada or EMA audit means FDA readiness
FDA-specific enforcement data showing where expectations differ from other jurisdictions
Scale transition
Clinical-to-commercial quality gaps discovered during or after the first inspection
Continuous intelligence on commercial-scale citation patterns before your PAI

Results

Platform Performance

Based on FDA Tracker's automated processing versus manual analyst workflows.

100%
Intelligence Coverage
Of FDA enforcement actions monitored and scored for relevance to your facility type, dosage form, and therapeutic area
148K+
Peer Visibility
Historical enforcement records searchable and filterable by CDMO, biologics, and cell therapy facility type
90%
Research Time
Less time on manual intelligence — FDA Tracker processes 4,000+ annual 483s in seconds versus weeks of manual reading
70%
Inspection Prep
Less time on pre-inspection research — custom checklists generated from 148,000+ indexed enforcement records in minutes

Next Step

Get Started

Every 483 at a peer CDMO is a signal about what inspectors will look for at yours. FDA Tracker brings every enforcement action to your quality team, filtered for your facility type and manufacturing processes.

Get Started
Exit